pexidartinib + paclitaxel

This is a combination of **pexidartinib**, a small molecule tyrosine kinase inhibitor of colony-stimulating factor 1 receptor (CSF-1R), FMS-like tyrosine kinase 3 (FLT3), and c-Kit (KIT), and **paclitaxel**, a microtubule-stabilizing chemotherapeutic agent. The combination has been studied in clinical trials for advanced solid tumors and high-risk early-stage breast cancer. Pexidartinib blocks CSF-1R signaling, reducing tumor-associated macrophage infiltration, which may help mitigate tumor growth and immune evasion. Paclitaxel disrupts cell division by stabilizing microtubules, leading to apoptosis of rapidly dividing cells. The pairing is based on preclinical evidence that CSF-1R inhibition can decrease immunosuppressive macrophages and enhance cytotoxic chemotherapy effects. In phase Ib/II studies, the combination showed manageable toxicity, notable hematologic and hepatic adverse events, and some partial and complete responses in advanced solid tumor patients. However, a trial in high-risk early-stage breast cancer found limited efficacy and concerns regarding serious hepatic toxicity[1][3][4][5].

Other names

pexidartinib and paclitaxelPLX3397 and paclitaxelPLX-3397 and paclitaxelPLX 3397 and paclitaxel